{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T14:13:27Z","timestamp":1782224007719,"version":"3.54.5"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s10787-025-01801-2","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T15:50:25Z","timestamp":1749138625000},"page":"2963-2976","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Bioactive compound nanoparticles for Alzheimer's disease"],"prefix":"10.1007","volume":"33","author":[{"given":"Neha","family":"Kshirsagar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwani","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3958-2813","authenticated-orcid":false,"given":"Meghraj","family":"Suryawanshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"1801_CR1","doi-asserted-by":"publisher","first-page":"7934442","DOI":"10.1155\/2022\/7934442","volume":"2022","author":"AT Aborode","year":"2022","unstructured":"Aborode AT, Pustake M, Awuah WA, Alwerdani M, Shah P, Yarlagadda R, Ahmad S, Silva Correia IF, Chandra A, Nansubuga EP, Abdul-Rahman T, Mehta A, Ali O, Amaka SO, Zu\u00f1iga YMH, Shkodina AD, Inya OC, Shen B, Alexiou A (2022) Targeting oxidative stress mechanisms to treat Alzheimer\u2019s and Parkinson\u2019s disease: a critical review. Oxid Med Cell Longev 2022:7934442. https:\/\/doi.org\/10.1155\/2022\/7934442","journal-title":"Oxid Med Cell Longev"},{"key":"1801_CR2","doi-asserted-by":"publisher","first-page":"5104","DOI":"10.1007\/s12011-021-03073-7","volume":"200","author":"OAR Abozaid","year":"2022","unstructured":"Abozaid OAR, Sallam MW, El-Sonbaty S, Aziza S, Emad B, Ahmed ESA (2022) Resveratrol-selenium nanoparticles alleviate neuroinflammation and neurotoxicity in a rat model of Alzheimer\u2019s disease by regulating Sirt1\/miRNA-134\/GSK3\u03b2 expression. Biol Trace Elem Res 200:5104\u20135114. https:\/\/doi.org\/10.1007\/s12011-021-03073-7","journal-title":"Biol Trace Elem Res"},{"key":"1801_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2021.105008","volume":"145","author":"M Agrawal","year":"2021","unstructured":"Agrawal M, Prathyusha E, Ahmed H, Dubey SK, Kesharwani P, Singhvi G, Naidu VGM, Alexander A (2021) Biomaterials in treatment of Alzheimer\u2019s disease. Neurochem Int 145:105008. https:\/\/doi.org\/10.1016\/j.neuint.2021.105008","journal-title":"Neurochem Int"},{"key":"1801_CR4","unstructured":"Ahmed HMAE-L, Ali MMK, Mohammed AMA-D, Shaheen HM, Batiha GEAE-W, Shalaby MA, Alamh AMAE (2023) Method of treating or preventing Alzheimer\u2019s disease. US11833181B1."},{"key":"1801_CR5","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1016\/j.bioactmat.2021.04.029","volume":"6","author":"BG Anand","year":"2021","unstructured":"Anand BG, Wu Q, Karthivashan G, Shejale KP, Amidian S, Wille H, Kar S (2021) Mimosine functionalized gold nanoparticles (Mimo-AuNPs) suppress \u03b2-amyloid aggregation and neuronal toxicity. Bioact Mater 6:4491\u20134505. https:\/\/doi.org\/10.1016\/j.bioactmat.2021.04.029","journal-title":"Bioact Mater"},{"key":"1801_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2023.122614","volume":"633","author":"S Ashique","year":"2023","unstructured":"Ashique S, Afzal O, Yasmin S, Hussain A, Altamimi MA, Webster TJ, Altamimi ASA (2023) Strategic nanocarriers to control neurodegenerative disorders: concept, challenges, and future perspective. Int J Pharm 633:122614. https:\/\/doi.org\/10.1016\/j.ijpharm.2023.122614","journal-title":"Int J Pharm"},{"key":"1801_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13052-018-0563-0","volume":"44","author":"CM Bellettato","year":"2018","unstructured":"Bellettato CM, Scarpa M (2018) Possible strategies to cross the blood\u2013brain barrier. Ital J Pediatr 44:131. https:\/\/doi.org\/10.1186\/s13052-018-0563-0","journal-title":"Ital J Pediatr"},{"key":"1801_CR8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.neuron.2015.09.036","volume":"88","author":"N Bien-Ly","year":"2015","unstructured":"Bien-Ly N, Boswell CA, Jeet S, Beach TG, Hoyte K, Luk W, Shihadeh V, Ulufatu S, Foreman O, Lu Y, DeVoss J, van der Brug M, Watts RJ (2015) Lack of widespread BBB disruption in Alzheimer\u2019s disease models: focus on therapeutic antibodies. Neuron 88:289\u2013297. https:\/\/doi.org\/10.1016\/j.neuron.2015.09.036","journal-title":"Neuron"},{"key":"1801_CR9","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.bpj.2014.06.024","volume":"107","author":"TS Carpenter","year":"2014","unstructured":"Carpenter TS, Kirshner DA, Lau EY, Wong SE, Nilmeier JP, Lightstone FC (2014) A method to predict blood\u2013brain barrier permeability of drug-like compounds using molecular dynamics simulations. Biophys J 107:630\u2013641. https:\/\/doi.org\/10.1016\/j.bpj.2014.06.024","journal-title":"Biophys J"},{"key":"1801_CR10","unstructured":"Castor TP, Alexander JS, Purdum G, Rios JD, Schrott LM, Tyler TA, Vizcaino MI (2019) Drug delivery system and method for the treatment of neuro-degenerative disease. US10485766B2."},{"key":"1801_CR11","doi-asserted-by":"publisher","first-page":"BSR20220324","DOI":"10.1042\/BSR20220324","volume":"43","author":"A Chakraborty","year":"2023","unstructured":"Chakraborty A, Mohapatra SS, Barik S, Roy I, Gupta B, Biswas A (2023) Impact of nanoparticles on amyloid \u03b2-induced Alzheimer\u2019s disease, tuberculosis, leprosy and cancer: a systematic review. Biosci Rep 43:BSR20220324. https:\/\/doi.org\/10.1042\/BSR20220324","journal-title":"Biosci Rep"},{"key":"1801_CR12","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.3390\/molecules23071820","volume":"23","author":"C Chen","year":"2018","unstructured":"Chen C, Lee M-H, Weng C-F, Leong MK (2018) Theoretical prediction of the complex P-glycoprotein substrate efflux based on the novel hierarchical support vector regression scheme. Molecules 23:1820. https:\/\/doi.org\/10.3390\/molecules23071820","journal-title":"Molecules"},{"key":"1801_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2022.931584","volume":"10","author":"Y-P Chen","year":"2022","unstructured":"Chen Y-P, Chou C-M, Chang T-Y, Ting H, Demb\u00e9l\u00e9 J, Chu Y-T, Liu T-P, Changou CA, Liu C-W, Chen C-T (2022) Bridging size and charge effects of mesoporous silica nanoparticles for crossing the blood-brain barrier. Front Chem 10:931584. https:\/\/doi.org\/10.3389\/fchem.2022.931584","journal-title":"Front Chem"},{"key":"1801_CR14","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.3390\/pharmaceutics16111395","volume":"16","author":"NS Chmelyuk","year":"2024","unstructured":"Chmelyuk NS, Nikitin AA, Vadekhina VV, Mitkevich VA, Abakumov MA (2024) Targeted magnetic nanoparticles for beta-amyloid detection. Pharmaceutics 16:1395. https:\/\/doi.org\/10.3390\/pharmaceutics16111395","journal-title":"Pharmaceutics"},{"key":"1801_CR15","doi-asserted-by":"publisher","first-page":"S567","DOI":"10.3233\/JAD-179941","volume":"64","author":"EN Cline","year":"2018","unstructured":"Cline EN, Bicca MA, Viola KL, Klein WL (2018) The amyloid-\u03b2 oligomer hypothesis: beginning of the third decade. J Alzheimers Dis 64:S567\u2013S610. https:\/\/doi.org\/10.3233\/JAD-179941","journal-title":"J Alzheimers Dis"},{"key":"1801_CR16","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.mattod.2020.02.001","volume":"37","author":"S Ding","year":"2020","unstructured":"Ding S, Khan AI, Cai X, Song Y, Lyu Z, Du D, Dutta P, Lin Y (2020) Overcoming blood\u2013brain barrier transport: Advances in nanoparticle-based drug delivery strategies. Mater Today 37:112\u2013125. https:\/\/doi.org\/10.1016\/j.mattod.2020.02.001","journal-title":"Mater Today"},{"key":"1801_CR17","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1080\/10717544.2018.1461955","volume":"25","author":"S Fan","year":"2018","unstructured":"Fan S, Zheng Y, Liu X, Fang W, Chen X, Liao W, Jing X, Lei M, Tao E, Ma Q, Zhang X, Guo R, Liu J (2018) Curcumin-loaded PLGA-PEG nanoparticles conjugated with B6 peptide for potential use in Alzheimer\u2019s disease. Drug Deliv 25:1091\u20131102. https:\/\/doi.org\/10.1080\/10717544.2018.1461955","journal-title":"Drug Deliv"},{"key":"1801_CR18","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.1021\/acsabm.4c00112","volume":"7","author":"BF Far","year":"2024","unstructured":"Far BF, Safaei M, Pourmolaei A, Adibamini S, Shirdel S, Shirdel S, Emadi R, Kaushik AK (2024) Exploring curcumin-loaded lipid-based nanomedicine as efficient targeted therapy for Alzheimer\u2019s diseases. ACS Appl Bio Mater 7:3535\u20133555. https:\/\/doi.org\/10.1021\/acsabm.4c00112","journal-title":"ACS Appl Bio Mater"},{"key":"1801_CR19","unstructured":"Frautschy SA, Cole GM (2015) Bioavailable curcuminoid formulations for treating Alzheimer\u2019s disease and other age-related disorders. US9192644B2."},{"key":"1801_CR20","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1166\/jbn.2013.1709","volume":"9","author":"RL Frozza","year":"2013","unstructured":"Frozza RL, Bernardi A, Hoppe JB, Meneghetti AB, Battastini AMO, Pohlmann AR, Guterres SS, Salbego C (2013) Lipid-Core Nanocapsules Improve the Effects of Resveratrol Against A\u03b2-Induced Neuroinflammation. J Biomed Nanotechnol 9:2086\u20132104. https:\/\/doi.org\/10.1166\/jbn.2013.1709","journal-title":"J Biomed Nanotechnol"},{"key":"1801_CR21","unstructured":"Gawdi R, Shumway KR, Emmady PD (2025) Physiology, blood brain barrier. In: StatPearls. StatPearls Publishing, Treasure Island"},{"key":"1801_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jconrel.2020.03.009","volume":"322","author":"X Gu","year":"2020","unstructured":"Gu X, Song Q, Zhang Q, Huang M, Zheng M, Chen J, Wei D, Chen J, Wei X, Chen H, Zheng G, Gao X (2020) Clearance of two organic nanoparticles from the brain via the paravascular pathway. J Controlled Release 322:31\u201341. https:\/\/doi.org\/10.1016\/j.jconrel.2020.03.009","journal-title":"J Controlled Release"},{"key":"1801_CR23","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/369488a0","volume":"369","author":"A Harada","year":"1994","unstructured":"Harada A, Oguchi K, Okabe S, Kuno J, Terada S, Ohshima T, Sato-Yoshitake R, Takei Y, Noda T, Hirokawa N (1994) Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature 369:488\u2013491. https:\/\/doi.org\/10.1038\/369488a0","journal-title":"Nature"},{"key":"1801_CR24","doi-asserted-by":"publisher","first-page":"160","DOI":"10.46747\/cfp.6903160","volume":"69","author":"D Hogan","year":"2023","unstructured":"Hogan D, Frank C (2023) Challenges with new treatments for Alzheimer disease: accelerated approval of aducanumab in the United States raises questions. Can Fam Physician 69:160\u2013161. https:\/\/doi.org\/10.46747\/cfp.6903160","journal-title":"Can Fam Physician"},{"key":"1801_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/S12640-016-9672-Y","author":"J Hort","year":"2016","unstructured":"Hort J (2016) Concentration of donepezil in the cerebrospinal fluid of AD patients: evaluation of dosage sufficiency in standard treatment strategy. Neurotox Res. https:\/\/doi.org\/10.1007\/S12640-016-9672-Y","journal-title":"Neurotox Res"},{"key":"1801_CR26","doi-asserted-by":"publisher","first-page":"1228679","DOI":"10.3389\/fcell.2023.1228679","volume":"11","author":"L Hu","year":"2023","unstructured":"Hu L, Tao Y, Jiang Y, Qin F (2023) Recent progress of nanomedicine in the treatment of Alzheimer\u2019s disease. Front Cell Dev Biol 11:1228679. https:\/\/doi.org\/10.3389\/fcell.2023.1228679","journal-title":"Front Cell Dev Biol"},{"key":"1801_CR27","doi-asserted-by":"publisher","first-page":"1130253","DOI":"10.3389\/fnagi.2023.1130253","volume":"15","author":"J Huang","year":"2023","unstructured":"Huang J, Huang N, Mao Q, Shi J, Qiu Y (2023) Natural bioactive compounds in Alzheimer\u2019s disease: From the perspective of type 3 diabetes mellitus. Front Aging Neurosci 15:1130253. https:\/\/doi.org\/10.3389\/fnagi.2023.1130253","journal-title":"Front Aging Neurosci"},{"key":"1801_CR28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00401-009-0486-3","volume":"118","author":"K Iqbal","year":"2009","unstructured":"Iqbal K, Liu F, Gong C-X, Alonso ADC, Grundke-Iqbal I (2009) Mechanisms of tau-induced neurodegeneration. Acta Neuropathol (Berl) 118:53\u201369. https:\/\/doi.org\/10.1007\/s00401-009-0486-3","journal-title":"Acta Neuropathol (Berl)"},{"key":"1801_CR29","doi-asserted-by":"publisher","first-page":"656","DOI":"10.2174\/156720510793611592","volume":"7","author":"K Iqbal","year":"2010","unstructured":"Iqbal K, Liu F, Gong C-X, Grundke-Iqbal I (2010) Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res 7:656\u2013664. https:\/\/doi.org\/10.2174\/156720510793611592","journal-title":"Curr Alzheimer Res"},{"key":"1801_CR30","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1159\/000508625","volume":"49","author":"KA Jellinger","year":"2020","unstructured":"Jellinger KA (2020) Pathobiological subtypes of Alzheimer disease. Dement Geriatr Cogn Disord 49:321\u2013333. https:\/\/doi.org\/10.1159\/000508625","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1801_CR31","unstructured":"Kaur S, Kumar P, Singh S (n.d) Oxidative Stress Targeting Amyloid Beta Accumulation and Clearance in Alzheimer\u2019s Disease: Insight into Pathological Mechanisms and Therapeutic Strategies. http:\/\/www.eurekaselect.com."},{"key":"1801_CR32","unstructured":"Kay DG, Maclellan A (2018) Composition and method for improving cognitive function and brain bioavailability of ginseng and ginsenosides and treating neurodegenerative disease and neurological disorders. WO2018148821A1."},{"key":"1801_CR33","doi-asserted-by":"publisher","first-page":"2203629","DOI":"10.1002\/smll.202203629","volume":"18","author":"H Li","year":"2022","unstructured":"Li H, Zha S, Li H, Liu H, Wong K, All AH (2022) Polymeric dendrimers as nanocarrier vectors for neurotheranostics. Small 18:2203629. https:\/\/doi.org\/10.1002\/smll.202203629","journal-title":"Small"},{"key":"1801_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1112435","author":"N Liu","year":"2023","unstructured":"Liu N, Ruan J, Li H, Fu J (2023) Nanoparticles loaded with natural medicines for the treatment of Alzheimer\u2019s disease. Front Neurosci. https:\/\/doi.org\/10.3389\/fnins.2023.1112435","journal-title":"Front Neurosci"},{"key":"1801_CR35","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/978-1-0716-4003-6_15","volume-title":"Computational toxicology: methods and protocols","author":"A Lopalco","year":"2025","unstructured":"Lopalco A, Iacobazzi RM, Lopedota AA, Denora N (2025) Recent advances in nanodrug delivery systems production, efficacy, safety, and toxicity. In: Nicolotti O (ed) Computational toxicology: methods and protocols. Springer US, New York, pp 303\u2013332. https:\/\/doi.org\/10.1007\/978-1-0716-4003-6_15"},{"key":"1801_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2024.101145","volume":"27","author":"R Ma","year":"2024","unstructured":"Ma R, Mu Q, Xi Y, Liu G, Liu C (2024) Nanotechnology for tau pathology in Alzheimer\u2019s disease. Mater Today Bio 27:101145. https:\/\/doi.org\/10.1016\/j.mtbio.2024.101145","journal-title":"Mater Today Bio"},{"key":"1801_CR37","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1042\/BST20170501","volume":"46","author":"R Macdonald","year":"2018","unstructured":"Macdonald R, Barnes K, Hastings C, Mortiboys H (2018) Mitochondrial abnormalities in Parkinson\u2019s disease and Alzheimer\u2019s disease: can mitochondria be targeted therapeutically? Biochem Soc Trans 46:891\u2013909. https:\/\/doi.org\/10.1042\/BST20170501","journal-title":"Biochem Soc Trans"},{"key":"1801_CR38","doi-asserted-by":"publisher","first-page":"4866","DOI":"10.3390\/molecules25204866","volume":"25","author":"E Manek","year":"2020","unstructured":"Manek E, Darvas F, Petroianu GA (2020) Use of Biodegradable, Chitosan-Based Nanoparticles in the Treatment of Alzheimer\u2019s Disease. Molecules 25:4866. https:\/\/doi.org\/10.3390\/molecules25204866","journal-title":"Molecules"},{"key":"1801_CR39","doi-asserted-by":"publisher","unstructured":"Manuel-Soto-Valdez, Jose-Francisco-F\u00e9lix-Rocha, Grecia-Jatzeny-Galv\u00e1n-Amaya, Nedra-Joana-P\u00e9rez-Garc\u00eda, Brissia-Lazalde-Medina, Manuel-Soto-Valdez, Jose-Francisco-F\u00e9lix-Rocha, Grecia-Jatzeny-Galv\u00e1n-Amaya, Nedra-Joana-P\u00e9rez-Garc\u00eda, Brissia-Lazalde-Medina, 2024. Genetic factors associated to Alzheimer\u2019s Disease. GSC Adv Res Rev 19:147\u2013155. https:\/\/doi.org\/10.30574\/gscarr.2024.19.3.0204","DOI":"10.30574\/gscarr.2024.19.3.0204"},{"key":"1801_CR40","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/S0090-9556(24)14950-1","volume":"27","author":"K Matsui","year":"1999","unstructured":"Matsui K, Mishima M, Nagai Y, Yuzuriha T, Yoshimura T (1999) Absorption, distribution, metabolism, and excretion of donepezil (Aricept) after a single oral administration to Rat. Drug Metab Dispos Biol Fate Chem 27:1406\u20131414","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"1801_CR41","doi-asserted-by":"publisher","first-page":"2400232","DOI":"10.1002\/smsc.202400232","volume":"4","author":"CD McLoughlin","year":"2024","unstructured":"McLoughlin CD, Nevins S, Stein JB, Khakbiz M, Lee K-B (2024) Overcoming the blood-brain barrier: multifunctional nanomaterial-based strategies for targeted drug delivery in neurological disorders. Small Sci 4:2400232. https:\/\/doi.org\/10.1002\/smsc.202400232","journal-title":"Small Sci"},{"key":"1801_CR42","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/em.21931","volume":"56","author":"L Migliore","year":"2015","unstructured":"Migliore L, Uboldi C, Di Bucchianico S, Copped\u00e8 F (2015) Nanomaterials and neurodegeneration. Environ Mol Mutagen 56:149\u2013170. https:\/\/doi.org\/10.1002\/em.21931","journal-title":"Environ Mol Mutagen"},{"key":"1801_CR43","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2174\/9789815256505124010010","volume-title":"Applications of nanoparticles in drug delivery and therapeutics","author":"S Mishra","year":"2024","unstructured":"Mishra S, Senthilkumar D, Yadav VK (2024) Current perspectives of nanotherapeutics for the treatment of Alzheimer\u2019s disease. In: Tripathy DB, Gupta A, Jain AK, Agarwal P (eds) Applications of nanoparticles in drug delivery and therapeutics. BENTHAM SCIENCE PUBLISHERS, pp 141\u2013165. https:\/\/doi.org\/10.2174\/9789815256505124010010"},{"key":"1801_CR44","doi-asserted-by":"publisher","first-page":"2207626","DOI":"10.1002\/smll.202207626","volume":"19","author":"F Mohebichamkhorami","year":"2023","unstructured":"Mohebichamkhorami F, Faizi M, Mahmoudifard M, Hajikarim-Hamedani A, Mohseni SS, Heidari A, Ghane Y, Khoramjouy M, Khayati M, Ghasemi R, Zali H, Hosseinzadeh S, Mostafavi E (2023) Microfluidic synthesis of ultrasmall chitosan\/graphene quantum dots particles for intranasal delivery in Alzheimer\u2019s disease treatment. Small 19:2207626. https:\/\/doi.org\/10.1002\/smll.202207626","journal-title":"Small"},{"key":"1801_CR45","unstructured":"Montine TJ, Corrada MM, Kawas C, Bukhari SA, White LR, Tian L, Cholerton B (n.d) Association of cognition and dementia with neuropathologic changes of Alzheimer disease and other conditions in the oldest old"},{"key":"1801_CR46","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/461895a","volume":"461","author":"L Mucke","year":"2009","unstructured":"Mucke L (2009) Alzheimer\u2019s disease. Nature 461:895\u2013897. https:\/\/doi.org\/10.1038\/461895a","journal-title":"Nature"},{"key":"1801_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2013.00083","author":"W Noble","year":"2013","unstructured":"Noble W, Hanger DP, Miller CC, Lovestone S (2013) The importance of tau phosphorylation for neurodegenerative diseases. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2013.00083","journal-title":"Front Neurol"},{"key":"1801_CR48","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1166\/jbn.2014.1719","volume":"10","author":"KP Pagar","year":"2014","unstructured":"Pagar KP, Sardar SM, Vavia PR (2014) Novel -lactide-depsipeptide polymeric carrier for enhanced brain uptake of rivastigmine in treatment of Alzheimer\u2019s disease. J Biomed Nanotechnol 10:415\u2013426. https:\/\/doi.org\/10.1166\/jbn.2014.1719","journal-title":"J Biomed Nanotechnol"},{"key":"1801_CR49","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.addr.2018.04.009","volume":"135","author":"Y Pan","year":"2018","unstructured":"Pan Y, Nicolazzo JA (2018) Impact of aging, Alzheimer\u2019s disease and Parkinson\u2019s disease on the blood\u2013brain barrier transport of therapeutics. Adv Drug Deliv Rev 135:62\u201374. https:\/\/doi.org\/10.1016\/j.addr.2018.04.009","journal-title":"Adv Drug Deliv Rev"},{"key":"1801_CR50","doi-asserted-by":"publisher","first-page":"13954","DOI":"10.3390\/ijms232213954","volume":"23","author":"E Passeri","year":"2022","unstructured":"Passeri E, Elkhoury K, Morsink M, Broersen K, Linder M, Tamayol A, Malaplate C, Yen FT, Arab-Tehrany E (2022) Alzheimer\u2019s Disease: treatment strategies and their limitations. Int J Mol Sci 23:13954. https:\/\/doi.org\/10.3390\/ijms232213954","journal-title":"Int J Mol Sci"},{"key":"1801_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/EXP.20230137","author":"S Pawar","year":"2024","unstructured":"Pawar S, Rauf MA, Abdelhady H, Iyer AK (2024) Tau-targeting nanoparticles for treatment of Alzheimer\u2019s disease. Exploration. https:\/\/doi.org\/10.1002\/EXP.20230137","journal-title":"Exploration"},{"key":"1801_CR52","doi-asserted-by":"publisher","first-page":"5657","DOI":"10.1002\/ptr.8012","volume":"37","author":"BC Phukan","year":"2023","unstructured":"Phukan BC, Roy R, Gahatraj I, Bhattacharya P, Borah A (2023) Therapeutic considerations of bioactive compounds in Alzheimer\u2019s disease and Parkinson\u2019s disease: Dissecting the molecular pathways. Phytother Res 37:5657\u20135699. https:\/\/doi.org\/10.1002\/ptr.8012","journal-title":"Phytother Res"},{"key":"1801_CR53","doi-asserted-by":"publisher","first-page":"7194","DOI":"10.1016\/j.biomaterials.2012.06.063","volume":"33","author":"R Prades","year":"2012","unstructured":"Prades R, Guerrero S, Araya E, Molina C, Salas E, Zurita E, Selva J, Egea G, L\u00f3pez-Iglesias C, Teixid\u00f3 M, Kogan MJ, Giralt E (2012) Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor. Biomaterials 33:7194\u20137205. https:\/\/doi.org\/10.1016\/j.biomaterials.2012.06.063","journal-title":"Biomaterials"},{"key":"1801_CR54","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.nbd.2017.06.005","volume":"106","author":"P Reilly","year":"2017","unstructured":"Reilly P, Winston CN, Baron KR, Trejo M, Rockenstein EM, Akers JC, Kfoury N, Diamond M, Masliah E, Rissman RA, Yuan SH (2017) Novel human neuronal tau model exhibiting neurofibrillary tangles and transcellular propagation. Neurobiol Dis 106:222\u2013234. https:\/\/doi.org\/10.1016\/j.nbd.2017.06.005","journal-title":"Neurobiol Dis"},{"key":"1801_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102291","volume":"97","author":"AK Roghani","year":"2024","unstructured":"Roghani AK, Garcia RI, Roghani A, Reddy A, Khemka S, Reddy RP, Pattoor V, Jacob M, Reddy PH, Sehar U (2024) Treating Alzheimer\u2019s disease using nanoparticle-mediated drug delivery strategies\/systems. Ageing Res Rev 97:102291. https:\/\/doi.org\/10.1016\/j.arr.2024.102291","journal-title":"Ageing Res Rev"},{"key":"1801_CR56","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1021\/acsbiomaterials.1c00514","volume":"7","author":"AK Singh","year":"2021","unstructured":"Singh AK, Singh SS, Rathore AS, Singh SP, Mishra G, Awasthi R, Mishra SK, Gautam V, Singh SK (2021) Lipid-coated MCM-41 mesoporous silica nanoparticles loaded with berberine improved inhibition of acetylcholine esterase and amyloid formation. ACS Biomater Sci Eng 7:3737\u20133753. https:\/\/doi.org\/10.1021\/acsbiomaterials.1c00514","journal-title":"ACS Biomater Sci Eng"},{"key":"1801_CR57","doi-asserted-by":"publisher","first-page":"12833","DOI":"10.1021\/acsomega.9b01411","volume":"4","author":"SK Sonawane","year":"2019","unstructured":"Sonawane SK, Ahmad A, Chinnathambi S (2019) Protein-capped metal nanoparticles inhibit tau aggregation in Alzheimer\u2019s disease. ACS Omega 4:12833\u201312840. https:\/\/doi.org\/10.1021\/acsomega.9b01411","journal-title":"ACS Omega"},{"key":"1801_CR58","doi-asserted-by":"publisher","first-page":"2403473","DOI":"10.1002\/advs.202403473","volume":"11","author":"Q Song","year":"2024","unstructured":"Song Q, Li J, Li T, Li H-W (2024) Nanomaterials that Aid in the diagnosis and treatment of Alzheimer\u2019s disease, resolving blood-brain barrier crossing ability. Adv Sci 11:2403473. https:\/\/doi.org\/10.1002\/advs.202403473","journal-title":"Adv Sci"},{"key":"1801_CR59","doi-asserted-by":"publisher","DOI":"10.47611\/jsrhs.v13i1.6167","author":"A Strofs","year":"2024","unstructured":"Strofs A (2024) Understanding Alzheimer\u2019s disease: exploring neuropsychiatric symptoms and treatment options. J Stud Res. https:\/\/doi.org\/10.47611\/jsrhs.v13i1.6167","journal-title":"J Stud Res"},{"key":"1801_CR60","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.colsurfb.2016.08.052","volume":"148","author":"D Sun","year":"2016","unstructured":"Sun D, Li N, Zhang W, Zhao Z, Mou Z, Huang D, Liu J, Wang W (2016) Design of PLGA-functionalized quercetin nanoparticles for potential use in Alzheimer\u2019s disease. Colloids Surf B Biointerfaces 148:116\u2013129. https:\/\/doi.org\/10.1016\/j.colsurfb.2016.08.052","journal-title":"Colloids Surf B Biointerfaces"},{"key":"1801_CR61","unstructured":"Sung H-W, Sonaje K, Nguyen H-N, Chuang E-Y, Tu H (2012) Pharmaceutical composition of nanoparticles. US8192718B1"},{"key":"1801_CR62","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jconrel.2017.08.033","volume":"264","author":"C Tapeinos","year":"2017","unstructured":"Tapeinos C, Battaglini M, Ciofani G (2017) Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J Controlled Release 264:306\u2013332. https:\/\/doi.org\/10.1016\/j.jconrel.2017.08.033","journal-title":"J Controlled Release"},{"key":"1801_CR63","doi-asserted-by":"publisher","unstructured":"Tosi G, Pederzoli F, Belletti D, Vandelli MA, Forni F, Duskey JT, Ruozi B (2019) Nanomedicine in Alzheimer\u2019s disease: amyloid beta targeting strategy. In: Progress in brain research. Elsevier, pp. 57\u201388. https:\/\/doi.org\/10.1016\/bs.pbr.2019.03.001","DOI":"10.1016\/bs.pbr.2019.03.001"},{"key":"1801_CR64","unstructured":"Tripathi V (2019) Modified resveratrol composition and use thereof. US20190343775A1."},{"key":"1801_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioadv.2022.213125","volume":"141","author":"SL van den Broek","year":"2022","unstructured":"van den Broek SL, Shalgunov V, Herth MM (2022) Transport of nanomedicines across the blood\u2013brain barrier: challenges and opportunities for imaging and therapy. Biomater Adv 141:213125. https:\/\/doi.org\/10.1016\/j.bioadv.2022.213125","journal-title":"Biomater Adv"},{"key":"1801_CR66","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3390\/ijms20020381","volume":"20","author":"KH Wong","year":"2019","unstructured":"Wong KH, Riaz MK, Xie Y, Zhang X, Liu Q, Chen H, Bian Z, Chen X, Lu A, Yang Z (2019) Review of current strategies for delivering Alzheimer\u2019s disease drugs across the blood\u2013brain barrier. Int J Mol Sci 20:381. https:\/\/doi.org\/10.3390\/ijms20020381","journal-title":"Int J Mol Sci"},{"key":"1801_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1249632","author":"R Xie","year":"2023","unstructured":"Xie R, Chen F, Ma Y, Hu W, Zheng Q, Cao J, Wu Y (2023) Network pharmacology-based analysis of marine cyanobacteria derived bioactive compounds for application to Alzheimer\u2019s disease. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2023.1249632","journal-title":"Front Pharmacol"},{"key":"1801_CR68","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.actbio.2015.06.035","volume":"25","author":"T Yin","year":"2015","unstructured":"Yin T, Yang L, Liu Y, Zhou X, Sun J, Liu J (2015) Sialic acid (SA)-modified selenium nanoparticles coated with a high blood\u2013brain barrier permeability peptide-B6 peptide for potential use in Alzheimer\u2019s disease. Acta Biomater 25:172\u2013183. https:\/\/doi.org\/10.1016\/j.actbio.2015.06.035","journal-title":"Acta Biomater"},{"key":"1801_CR69","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1586\/14737175.2014.915740","volume":"14","author":"H Zetterberg","year":"2014","unstructured":"Zetterberg H, Mattsson N (2014) Understanding the cause of sporadic Alzheimer\u2019s disease. Expert Rev Neurother 14:621\u2013630. https:\/\/doi.org\/10.1586\/14737175.2014.915740","journal-title":"Expert Rev Neurother"},{"key":"1801_CR70","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3390\/brainsci11020278","volume":"11","author":"B Zhang","year":"2021","unstructured":"Zhang B, Lin L, Wu S, Al-Masqari ZHMA (2021a) Multiple subtypes of Alzheimer\u2019s disease base on brain atrophy pattern. Brain Sci 11:278. https:\/\/doi.org\/10.3390\/brainsci11020278","journal-title":"Brain Sci"},{"key":"1801_CR71","doi-asserted-by":"publisher","first-page":"313","DOI":"10.14283\/jpad.2021.15","volume":"8","author":"X-X Zhang","year":"2021","unstructured":"Zhang X-X, Tian Y, Wang Z-T, Ma Y-H, Tan L, Yu J-T (2021b) The epidemiology of Alzheimer\u2019s disease modifiable risk factors and prevention. J Prev Alzheimers Dis. 8:313\u2013321. https:\/\/doi.org\/10.14283\/jpad.2021.15","journal-title":"J Prev Alzheimers Dis."},{"key":"1801_CR72","unstructured":"Zhou J, Ding Y, Zhang H (2021) Natural nanoparticle-medicine composition for treating Alzheimer\u2019s disease, preparation method therefor and application thereof. US20210220288A1."},{"key":"1801_CR73","doi-asserted-by":"publisher","first-page":"23328","DOI":"10.1021\/acsami.1c00257","volume":"13","author":"L Zhu","year":"2021","unstructured":"Zhu L, Xu L, Wu X, Deng F, Ma R, Liu Y, Huang F, Shi L (2021) Tau-Targeted Multifunctional Nanoinhibitor for Alzheimer\u2019s Disease. ACS Appl Mater Interfaces 13:23328\u201323338. https:\/\/doi.org\/10.1021\/acsami.1c00257","journal-title":"ACS Appl Mater Interfaces"},{"key":"1801_CR74","unstructured":"\u5218\u519b, \u5ed6\u65fa, \u65b9\u6587\u4e3d, \u718a\u9e66, \u962e\u7389\u5a77, \u8303\u80dc\u8bfa, \u90d1\u96e8\u79cb, \u8c37\u8d1d\u8d1d, \u5f20\u84d3, \u674e\u6021, \u4f59\u7fa4, \u9ea6\u6f46\u4ec1, \u66f9\u5fd7\u6bd3, 2022. \u4e00\u79cd\u7528\u4e8e\u8bca\u7597\u963f\u5c14\u5179\u6d77\u9ed8\u75c7\u7684\u7eb3\u7c73\u590d\u5408\u836f\u7269. CN110559454B."},{"key":"1801_CR75","unstructured":"\u5218\u7389, \u84dd\u548f, \u9093\u7acb, \u9a6c\u6625\u94ed, \u9648\u6cf0\u701b, 2019. \u4e00\u79cd\u7528\u4e8e\u963f\u5c14\u8328\u6d77\u9ed8\u75c5\u7684\u8bca\u7597\u4e00\u4f53\u5316\u5236\u5242\u53ca\u5176\u5236\u5907\u65b9\u6cd5. CN109395093A."}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01801-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-025-01801-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01801-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T19:04:39Z","timestamp":1751396679000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-025-01801-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":75,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1801"],"URL":"https:\/\/doi.org\/10.1007\/s10787-025-01801-2","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"25 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}